COL4A1 Polyclonal Antibody

    • Catalog No.:YT1024
    • Applications:WB;IHC;IF;ELISA
    • Reactivity:Human;Mouse
      • Target:
      • Collagen IV
      • Fields:
      • >>PI3K-Akt signaling pathway;>>Focal adhesion;>>ECM-receptor interaction;>>Relaxin signaling pathway;>>AGE-RAGE signaling pathway in diabetic complications;>>Protein digestion and absorption;>>Amoebiasis;>>Human papillomavirus infection;>>Pathways in cancer;>>Small cell lung cancer
      • Gene Name:
      • COL4A1
      • Protein Name:
      • Collagen alpha-1(IV) chain
      • Human Gene Id:
      • 1282
      • Human Swiss Prot No:
      • P02462
      • Mouse Swiss Prot No:
      • P02463
      • Immunogen:
      • The antiserum was produced against synthesized peptide derived from human Collagen IV. AA range:11-60
      • Specificity:
      • COL4A1 Polyclonal Antibody detects endogenous levels of COL4A1 protein.
      • Formulation:
      • Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
      • Source:
      • Polyclonal, Rabbit,IgG
      • Dilution:
      • WB 1:500 - 1:2000. IHC 1:100 - 1:300. ELISA: 1:20000.. IF 1:50-200
      • Purification:
      • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
      • Concentration:
      • 1 mg/ml
      • Storage Stability:
      • -15°C to -25°C/1 year(Do not lower than -25°C)
      • Other Name:
      • COL4A1;Collagen alpha-1(IV) chain
      • Observed Band(KD):
      • 160kD
      • Background:
      • This gene encodes a type IV collagen alpha protein. Type IV collagen proteins are integral components of basement membranes. This gene shares a bidirectional promoter with a paralogous gene on the opposite strand. The protein consists of an amino-terminal 7S domain, a triple-helix forming collagenous domain, and a carboxy-terminal non-collagenous domain. It functions as part of a heterotrimer and interacts with other extracellular matrix components such as perlecans, proteoglycans, and laminins. In addition, proteolytic cleavage of the non-collagenous carboxy-terminal domain results in a biologically active fragment known as arresten, which has anti-angiogenic and tumor suppressor properties. Mutations in this gene cause porencephaly, cerebrovascular disease, and renal and muscular defects. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2014],
      • Function:
      • disease:Defects in COL4A1 are a cause of brain small vessel disease with hemorrhage [MIM:607595]. Brain small vessel diseases underlie 20 to 30 percent of ischemic strokes and a larger proportion of intracerebral hemorrhages. Inheritance is autosomal dominant.,disease:Defects in COL4A1 are a cause of porencephaly type 1 [MIM:175780]; also known as encephaloclastic porencephaly. Porencephaly is a term used for any cavitation or cerebrospinal fluid-filled cyst in the brain. Porencephaly type 1 is usually unilateral and results from focal destructive lesions such as fetal vascular occlusion or birth trauma. Inheritance is autosomal dominant.,disease:Defects in COL4A1 are the cause of hereditary angiopathy with nephropathy, aneurysms, and muscle cramps (HANAC) [MIM:611773]. The clinical renal manifestations include hematuria and bilateral large cysts. Histologic analysis revealed complex bas
      • Subcellular Location:
      • Secreted, extracellular space, extracellular matrix, basement membrane .
      • Expression:
      • Highly expressed in placenta.
      • Products Images
      • Prenatal bisphenol S exposure induces hepatic lipid deposition in male mice offspring through downregulation of adipose-derived exosomal miR-29a-3p JOURNAL OF HAZARDOUS MATERIALS Guizhen Du IF Mouse AML12 hepatocytes
      • Western Blot analysis of mouse-musle cells using COL4A1 Polyclonal Antibody diluted at 1:500
      • Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using Collagen IV Antibody. The picture on the right is blocked with the synthesized peptide.
      • Western blot analysis of lysates from HeLa cells, using Collagen IV Antibody. The lane on the right is blocked with the synthesized peptide.